Kawasaki et al. demonstrated that FAM111B modulates p16 levels by directly interacting with and degrading this molecule, thereby augmenting cyclin D1-CDK4 activity in lung adenocarcinoma. Here, FAM111B is linked to lung adenocarcinoma.